| 基于网络药理学及实验验证探究芪苈强心胶囊治疗射血分数保留型心衰的作用机制 |
| |
| 引用本文： | 郝佳梦,常丽萍,王璐,刘焕,陈檬,侯斌,周璐恒,侯云龙.基于网络药理学及实验验证探究芪苈强心胶囊治疗射血分数保留型心衰的作用机制[J].中草药,2022,53(14):4365-4375. |
| |
| 作者姓名： | 郝佳梦 常丽萍 王璐 刘焕 陈檬 侯斌 周璐恒 侯云龙 |
| |
| 作者单位： | 河北以岭医院国家中医药管理局重点研究室(心脑血管络病), 河北 石家庄 050023;络病研究与创新中药国家重点实验室, 河北石家庄 050023;河北省络病重点实验室, 河北石家庄 050023;石家庄以岭药业股份有限公司, 河北石家庄 050023;河北省络病重点实验室, 河北石家庄 050023;石家庄以岭药业股份有限公司, 河北石家庄 050023;络病研究与创新中药国家重点实验室, 河北石家庄 050023;河北以岭医院国家中医药管理局重点研究室(心脑血管络病), 河北 石家庄 050023;石家庄以岭药业股份有限公司, 河北石家庄 050023 |
| |
| 基金项目： | 国家重点研发计划"中医药现代化研究"重点专项资助项目(2017YFC1700501);河北省自然科学基金资助项目(H2019106059);河北省中医药管理局科研计划项目(Z2022020) |
| |
| 摘 要： | 目的 基于网络药理学及实验验证探讨芪苈强心胶囊治疗射血分数保留型心衰（heart failure with preserved ejection fraction,HFpEF）的作用机制。方法 将44个明确鉴定的芪苈强心胶囊体内代谢物检识有效成分,利用Swisstargetprediction、pharmmapper平台预测化合物靶点,OMIM、DisGenet、GenCard数据库中检索HFpEF疾病靶点;取交集靶点,利用String数据库和Cytoscape 3.7.2软件进行蛋白质-蛋白质相互作用（protein-protein interaction,PPI）和拓扑分析;Metescape平台对共同靶点进行基因本体（gene ontology,GO）功能富集分析及京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes,KEGG）通路富集分析。构建醋酸脱氧皮质酮（deoxycorticosterone acetate,DOCA）盐敏感型HFpEF大鼠模型,给予沙库巴曲缬沙坦或芪苈强心胶囊进行干预,给药8周后,利用小动物超声成像系统...
|
| 关 键 词： | 网络药理学 芪苈强心胶囊 射血分数保留型心衰 内皮功能 脉络学说 环磷酸鸟苷-蛋白激酶G1通路 |
| 修稿时间： | 2022/2/23 0:00:00 |
Mechanism of Qili Qiangxin Capsule in treatment of heart failure with preserved ejection fraction based on network pharmacology and experimental verification |
| |
| HAO Jia-meng,CHANG Li-ping,WANG Lu,LIU Huan,CHEN Meng,HOU Bin,ZHOU Lu-heng,HOU Yun-long.Mechanism of Qili Qiangxin Capsule in treatment of heart failure with preserved ejection fraction based on network pharmacology and experimental verification[J].Chinese Traditional and Herbal Drugs,2022,53(14):4365-4375. |
| |
| Authors: | HAO Jia-meng CHANG Li-ping WANG Lu LIU Huan CHEN Meng HOU Bin ZHOU Lu-heng HOU Yun-long |
| |
| Institution: | Hebei Medical University, Shijiazhuang 050017, China;Key Research Office of State Administration of Traditional Chinese Medicine (Cardiovascular and Cerebrovascular Diseases), Hebei Yiling Hospital, Shijiazhuang 050023, China;State Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang 050023, China;Hebei Key Laboratory of Collateral Diseases, Shijiazhuang 050023, China;Shijiazhuang Yiling Pharmaceutical Co., Ltd., Shijiazhuang 050023, China;Hebei Key Laboratory of Collateral Diseases, Shijiazhuang 050023, China;Shijiazhuang Yiling Pharmaceutical Co., Ltd., Shijiazhuang 050023, China;State Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang 050023, China; Hebei Medical University, Shijiazhuang 050017, China;Key Research Office of State Administration of Traditional Chinese Medicine (Cardiovascular and Cerebrovascular Diseases), Hebei Yiling Hospital, Shijiazhuang 050023, China;Shijiazhuang Yiling Pharmaceutical Co., Ltd., Shijiazhuang 050023, China |
| |
| Abstract: | |
| |
| Keywords: | network pharmacology|Qili Qiangxin Capsule|heart failure with preserved ejection fraction|endothelial function|choroid theory|cGMP-PKG1 pathway |
|
| 点击此处可从《中草药》浏览原始摘要信息 |
| 点击此处可从《中草药》下载免费的PDF全文 |
|
